Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled for elective Cardiac or Thoracic Surgery.~* Age \> 18 years of age.~Exclusion Criteria:~* Patients with a clinical suspicion or a documented history of DVT/PE~* Patients who may require anticoagulation during the post-op period. (i.e. Patients with a history of A-fib, scheduled for a MAZE procedure or placement of a mechanical valve, or those on Coumadin/IV heparin preoperatively)~* Patients who have a history of HIT or if there is a suspicion of the patient having HIT pre-operatively.~* Documented allergy to heparin, desirudin, or lepirudin~* Patients with a history of coagulation disorder~* Platelet count\< 100 X109 /dl~* Active bleeding~* Serum Creatinine ≥ 1.5 mg/dl or CrCl ≤ 30 ml/min~* Patients with a baseline coagulopathy (INR \> 1.5 or aPTT \> 45 sec)~* Patients with liver disease~* Pregnancy~* Patients who require ventricular assist devices before or after surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heparin (Type: ACTIVE_COMPARATOR): Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
- Desirudin (Iprivask™) (Type: EXPERIMENTAL): Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.

Based on this trial design, predict the completion outcome and termination type (if applicable).